您当前所在的位置:首页 > 产品中心 > 产品信息
Sulfamoxole_分子结构_CAS_729-99-7)
点击图片或这里关闭

Sulfamoxole

产品号 DB08798 公司名称 DrugBank
CAS号 729-99-7 公司网站 http://www.ualberta.ca/
分子式 C11H13N3O3S 电 话 (780) 492-3111
分子量 267.30422 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 6399

产品价格信息

请登录

产品别名

标题
Sulfamoxole
IUPAC标准名
4-amino-N-(dimethyl-1,3-oxazol-2-yl)benzene-1-sulfonamide
IUPAC传统名
sulfamoxole
商标名
Nuprin
Vetranal
Tardamid
Sulfavigor
Justamil
Sulfmidil
别名
Sulfono
Sulphamoxole
Sulfamoxol
Sulfamoxolum

产品登记号

CAS号 729-99-7

产品性质

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Sulfamoxole is a sulfonamide antibacterial.
Indication For the treatment of bacterial infection.
Pharmacology Sulfamoxole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
Toxicity Oral Rat LD50: > 12500 mg/kg; Intravenous Mouse LD50: 1 g/kg

Affected Organisms
Enteric bacteria and other eubacteria
References
DUGGER JA: Sulfamoxole (Nuprin), a new sulfonamide, in pediatric practice. J New Drugs. 1961 Sep-Oct;1:223-9. [Pubmed]
External Links
Wikipedia

参考文献

  • DUGGER JA: Sulfamoxole (Nuprin), a new sulfonamide, in pediatric practice. J New Drugs. 1961 Sep-Oct;1:223-9. Pubmed